Prasugrel: 6 agencies, 2009–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 15 years separate the first record, 22 Jul 2009 at HAS (France), from the most recent, 2024 at PBAC (Australia).
PHARMAC (New Zealand) changed its position: not recommended on 17 Feb 2011, recommended by 17 Oct 2022, after a resubmission.
No assessment is on file from AWMSG (Wales), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for prasugrel by the agencies that label one in English (NICE, PBAC and SMC).
2 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess prasugrel, on 22 Jul 2009; PBAC (Australia) did not open a file until 2024 — an unusually long tail of 15 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 9 years in total.
Restriction is doing real work here: 4 of 12 decisive outcomes narrowed prasugrel to a subgroup rather than accepting or refusing it outright, at PHARMAC (New Zealand), SMC (Scotland) and TLV (Sweden).
4 of the 6 agencies here assessed prasugrel more than once, PHARMAC (New Zealand) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for prasugrel.
The full ledger for prasugrel reads 5 recommended, 4 restricted, 3 not recommended and 3 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Acute coronary syndrome (ACS) | Recommended | source |
| HAS (France) | 15 Apr 2015 | Listing renewal (Transparency Committee) | SMR substantial · ASMR V | source |
| NICE (England) | 23 Jul 2014 | NICE TA317 | recommended | source |
| PHARMAC (New Zealand) | 14 Feb 2013 | Percutaneous coronary intervention - immediate PCI for STEMI patients | PTAC advice: No Formal Recommendation · decision reached | source |
| TLV (Sweden) | 14 Apr 2010 | Efient ingår i högkostnadsskyddet med ny begränsning | restricted subsidy | source |
10 further decisions for prasugrel, across 5 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- rivaroxaban — same ATC class B01A — Antithrombotics
- apixaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- dabigatran — same ATC class B01A — Antithrombotics
- fondaparinux — same ATC class B01A — Antithrombotics
- ticagrelor — same ATC class B01A — Antithrombotics
Coverage: 15 decisions for prasugrel from 6 agencies, 2009 to 2024. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.